Can Evenity (romosozumab) be administered 28 days after the last injection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Evenity Dosing Interval After Missed Dose

If an Evenity dose is missed, it should be administered as soon as it can be rescheduled, and thereafter scheduled every month from the date of that last dose—there is no specific prohibition against administering at 28 days after the previous injection. 1

FDA-Approved Dosing Schedule

  • The recommended dosing interval for Evenity is once every month (210 mg subcutaneously), administered as two separate 105 mg injections, for a total treatment duration of 12 monthly doses. 1

  • If a dose is missed, the FDA label explicitly states to "administer as soon as it can be rescheduled" and then "EVENITY can be scheduled every month from the date of the last dose." 1

  • This guidance indicates flexibility in the dosing schedule when doses are delayed, allowing resumption of monthly dosing from whenever the missed dose is actually given. 1

Clinical Context and Practical Application

  • A 28-day interval (4 weeks) falls within the typical definition of "monthly" dosing used in clinical practice, and the FDA label does not specify a minimum interval that must elapse before the next dose. 1

  • The critical instruction is that subsequent doses should be scheduled monthly from the date of the last administered dose, not from the originally planned schedule. 1

  • Patients must receive adequate calcium and vitamin D supplementation throughout the 12-month treatment course with Evenity. 1

Important Safety Considerations

  • Evenity is contraindicated in patients with a history of myocardial infarction or stroke, as cardiovascular events were observed in clinical trials. 2, 3

  • Hypocalcemia must be corrected prior to initiating each dose of Evenity. 3, 4

  • After completing the 12-month Evenity treatment course, patients should transition to an antiresorptive agent (such as denosumab or a bisphosphonate) to maintain or further increase bone mineral density gains. 3, 5

  • Evenity should be reserved for postmenopausal women at very high fracture risk, ideally as first-line treatment after a recent major fracture (within 2 years). 2

References

Research

Romosozumab: A Novel Agent in the Treatment for Postmenopausal Osteoporosis.

The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians, 2021

Research

Romosozumab: A first-in-class sclerostin inhibitor for osteoporosis.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2020

Research

Romosozumab Treatment in Postmenopausal Women with Osteoporosis.

The New England journal of medicine, 2016

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.